Scientists have discovered a new way of attacking oesophageal cancer cells that could make use of an existing drug in a new approach to treatment.
Their study discovered a genetic weakness or 'Achilles' heel' in oesophageal cancer cells that makes them particularly sensitive to a drug called ibrutinib which is already used to treat blood cancer.
A team at The Institute of Cancer Research, London, demonstrated that oesophageal cancer cells with a cancer-causing mutation in a gene called MYC become dependent upon or 'addicted' to a second gene, BTK.
By blocking the function of BTK using ibrutinib, the researchers were able to kill oesophageal cancer cells grown in the lab, leaving normal cells relatively unaffected.
Attacking 'addicted' cancer cells in this way, a concept known as synthetic lethality, could open up a whole new avenue of treatment for oesophageal cancer -- a disease which affects 9,000 people a year in the UK.
For many patients with oesophageal cancer, the success of existing treatments is limited. The new work is aimed at improving this situation.
The study is published today (Tuesday) in the journal Gut, and was funded by Cancer Research UK, The Institute of Cancer Research (ICR), Jansen Ltd., Pharmacyclics Pharmaceuticals, and the NIHR Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the ICR.
Researchers are now assessing whether ibrutinib will work in oesophageal cancer patients with MYC mutations, in a phase II clinical trial at The Royal Marsden.
By assessing whether patients with MYC-mutated oesophageal cancers respond to ibrutinib, the researchers hope to test whether the laboratory findings translate into an improved way of treating the disease.
To identify this deadly addiction, researchers used a systematic approach, assessing the sensitivity of a large number of oesophageal cancer cells to cancer drugs that are already used in the treatment of other forms of cancer.
In parallel, they also assessed, one by one, the effects of inactivating 720 key genes on cancer cells. By integrating these two approaches, the scientists found the link between BTK addiction and ibrutinib sensitivity in oesophageal cancer cells.
As well as using this information to design a new clinical trial, the researchers also made all of the data generated in the study publicly available, so that other researchers worldwide can use the information to design other approaches for treating this aggressive disease.
Professor Chris Lord, Professor of Cancer Genomics at The Institute of Cancer Research, London, said:
"The DNA of cancer cells tends to be extremely mutated - whilst these mutations cause cancer, they also often make cells addicted to genes normal cells are not.
"Finding which genes cancers are addicted to is an exciting approach for identifying new ways of attacking tumours. We can now systematically identify genes which cancer cells need but healthy cells can live without - offering up the potential of precision therapies that have fewer side-effects than conventional treatments.
"Oesophageal cancers are often very hard to control. Our laboratory work suggests that an existing drug, which we know is safe, could be used in MYC-mutated patients. Our hope is that these results are reproduced in clinical trials."
Dr Irene Chong, NIHR BRC Clinician Scientist at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, said:
"Survival rates for patients with oesophageal cancer remain very poor, especially once the disease has started spreading round the body. We urgently need new treatment options that attack the disease in novel ways.
"Our new study has identified a potential Achilles' heel in some forms of oesophageal cancer, which we believe could be exploited by new treatments. And because there is an existing drug for other forms of cancer which attacks this weakness, we can test out our new approach rapidly in clinical trials."
Professor Karen Vousden, Cancer Research UK's chief scientist, said:
"By scrutinising the genetics of oesophageal cancer cells in the lab, this research has identified an existing drug that could be effective against oesophageal cancers with a certain genetic makeup. If clinical trials show that this drug is effective, this work could lead to a new treatment for some oesophageal cancer patients, which is urgently needed for this hard-to-treat disease."
For more information please contact Claire Hastings in the ICR press office on 020 7153 5380 or firstname.lastname@example.org. For enquiries out of hours, please call 07595 963 613.
Notes to editors
The Institute of Cancer Research, London, is one of the world's most influential cancer research organisations.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
A college of the University of London, the ICR is the UK's top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.